<DOC>
	<DOC>NCT01215981</DOC>
	<brief_summary>Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.</brief_summary>
	<brief_title>Influenza Vaccine Post Allogeneic Transplant</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patient Population HSCT recipients who are greater than 60 days post transplant. Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant Show neutrophil recovery, platelet count &gt; 50,000/mm3 (may be transfused), no known disease relapse No history of previous allergic reaction to influenza vaccine, known egg allergy or GuillanBarre Syndrome No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months Controls: Age 18 to 50 years No history of previous allergic reaction to influenza vaccine, known egg allergy or GuillanBarre Syndrome No flu vaccine in previous 4 months</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>influenza vaccine</keyword>
</DOC>